Activation of dendritic cell subpopulations in viral infection
==============================================================

Dendritic cells (DCs), which are present in the tissues of all organs as well as in the circulation and in lymphatic organs, are targets for infection by many different viruses. Viruses entering the body through epithelial surfaces or directly via the blood stream encounter DCs at early time points during infection. DCs are unique in their capacity to migrate from the periphery to lymphoid organs or from the blood stream into lymphatic and peripheral tissues. Virus-infected DCs can therefore transport viruses to other parts of the organism and thus contribute to the spreading of the pathogens to many organs during systemic infection. However, DCs are also equipped with a range of receptors (for example Toll-like receptors, TLRs) that recognize conserved molecular patterns of viruses -- either viral proteins or viral nucleic acids with specific distinguishing features ([@bib70]; [@bib61], [@bib62]; [@bib96]). Triggering of these pattern recognition receptors in virus-infected DCs initiates the innate antiviral immune response, which is essential for limiting further viral dissemination ([@bib22]; [@bib61]). The DCs themselves produce inflammatory cytokines and antiviral interferons in response to viral infection. In addition DCs express ligands for activating receptors on the surface of natural killer (NK) cells leading to activation of this innate antiviral effector cell type ([@bib4]). DCs are experts in the processing and presentation of viral antigens on MHC class I as well as crosspresentation on MHC class II. The antigen presenting function of DCs is critically involved in the generation of efficient adaptive immunity against viruses ([@bib11]). DC activation by viruses via pattern recognition receptors provides the 2nd and 3rd signals required for the priming of naïve-specific T lymphocytes and their differentiation into effector T cells.

DC subpopulations fulfill specific tasks in the generation of antiviral immune responses. Plasmacytoid DCs (pDC), which have also been described as natural interferon producing cells ([@bib84]; [@bib87]) represent a specialized subset of DCs characterized by their ability to express large amounts of type I interferons and interferon-induced genes in response to viruses as well as synthetic TLR7 and TLR9 ligands ([@bib17]; [@bib61], [@bib60]; [@bib100]).

In response to many viruses pDCs produce 10- to 100-fold more type I interferon on a single cell basis than other cell types such as conventional DC or macrophages ([@bib20]). In many viral infections pDCs have been shown to release the first wave of type I interferons and thus support subsequent steps of antiviral immunity, including NK cell activation, Th1 cell and CTL differentiation ([@bib21], [@bib22]; [@bib61]; [@bib18]). It has been shown *in vivo* and *in vitro* however, that cells other than pDCs (for example conventional DCs, macrophages and non-immune cells), also significantly contribute to type I IFN responses during viral infection despite the lower amount of type I interferon produced per cell ([@bib24]; [@bib7]; [@bib61]).

In contrast to other DC populations, pDCs are less efficient in presenting antigens. Several studies report that pDCs are capable of presenting antigens to T cells and triggering T cell proliferation and differentiation to effector cells ([@bib13]; [@bib22]; [@bib92]; [@bib94]). However, initial priming of T cell responses in many viral infections relies on conventional DCs, especially the CD8*α* ^+^ DCs in the murine system ([@bib11]). In addition it has been reported recently that pDCs activated via TLRs may also induce regulatory T cells ([@bib80]), which may inhibit the expansion and differentiation of antiviral T lymphocytes to prevent overstimulation of the immune system.

What is the molecular basis for the rapid and robust interferon production in pDCs? pDCs recognize viruses via TLRs, particularly via the endosomally located TLR7, TLR8 and TLR9. Downstream signaling of TLR7/8 and TLR9 leads to the activation of IRF7, which is the central transcription factor for expression of type I interferon and interferon inducible genes ([@bib43]). In contrast to most other cell types pDCs show constitutive expression of IRF7 which is required for the rapid and potent production of the full range of type I IFNs ([@bib49]; [@bib57]). pDC are unique in that IFN-*α* expression is induced by ligands of TLR7/8 and TLR9 via a supramolecular complex formed between MyD88, TRAF6, IRAK1/4 and IRF7, which leads to direct activation of the constitutively expressed IRF7 only in this specialized cell type ([@bib41]; [@bib55]).

The cytoplasmatic RNA helicases RIG-I or MDA5 do not contribute to viral recognition in pDCs, because the response of pDCs from mice deficient in RIG-I or the essential signaling adaptor of RIG-I and MDA5 to RNA viruses is comparable to that of wild-type mice ([@bib53]). It has been demonstrated in several studies that pDCs recognize herpes simplex virus type 1 and 2 (HSV-1 and -2) ([@bib62]; [@bib70]), murine cytomegalovirus (MCMV) ([@bib61]) and also recombinant replication-deficient adenovirus ([@bib9]), via TLR9, whereas Influenza virus ([@bib7]; [@bib25]), vesicular stomatitis virus (VSV), Newcastle disease virus (NDV) and Sendai virus (SeV) ([@bib71]) are recognized by TLR7 in pDCs.

Many viruses that enter pDCs and trigger TLRs are prevented from expressing viral genes and replicating their genome. Thus, the activation of the type I IFN response in pDCs most often is not counteracted by viral immune evasion strategies. Accordingly, active viral replication is not required for the induction of type I IFN production in pDCs for many enveloped viruses, for example Influenza virus or herpes viruses ([@bib62]; [@bib70]). Following endocytic uptake it is assumed that these viruses are retained in acidified endosomal compartments, where TLR7 and TLR9 are localized, so that the viral particles are degraded and viral nucleic acids come into contact with TLR7 and TLR9. A recent report, however, clearly demonstrates that cytosolic viral replication and a transport mechanism involving autophagy is necessary for triggering the TLR7-dependent response to other RNA viruses, such as VSV or SeV in pDCs ([@bib66]). After infection of pDCs with these RNA viruses, viral replication intermediates in the cytosol are internalized in autophagic vesicles which are then directed towards the TLR7-containing lysosomes, where recognition of the viral RNA occurs ([@bib66]).

Toll-like receptors recognize viral DNA and RNA
===============================================

The Toll-like receptors are a family of type I transmembrane glycoproteins characterized by the extracellular leucine-rich-repeat domain and the cytoplasmatic TIR domain for downstream signaling, which is homologous to the TIR domain of the IL-1 and IL-18 receptors. TLR expression is predominantly found in various immune cells like dendritic cells, macrophages, B cells and some types of T cells. Moreover TLRs can be expressed by non-immune cells such as fibroblasts and epithelial cells. Among the TLR family a subgroup of mainly intracellularly localized TLRs (TLR3, 7, 8, 9) can be differentiated from TLRs which are expressed on the cell surface (TLR1, 2, 4, 5, 6, 5). Whereas surface-expressed TLRs are mainly involved in the recognition of bacterial and fungal cell wall components as well as some viral proteins, the intracellular/endosomal TLRs have the capacity to detect microbial nucleic acids, particularly viral DNA and RNA. Apart from activating the NF*κ*B and MAPK signaling pathways leading to inflammatory cytokine and chemokine production as well as costimulatory molecule expression, the intracellularly localized nucleic acid recognition receptors TLR3, 7, 8 and 9 specifically trigger type I interferon production via MyD88- and TRIF-dependent signaling pathways.

Toll-like receptor 3
--------------------

TLR3 binds double-stranded (ds) RNA which is found in dsRNA viruses, such as reovirus, or is generated during replication of single-stranded (ss) RNA viruses such as West Nile virus ([@bib110]) or respiratory syncytial virus ([@bib89]) or as a by-product of symmetrical transcription of viral DNA, for example from herpes viruses. Another ligand for TLR3 is poly(I:C) which is a synthetic dsRNA mimicking viral infection ([@bib2]). Studies in TLR3^−/−^ mice identified poly(I:C) and dsRNA as ligands for TLR3, which induce type I IFN and proinflammatory cytokine production. Up-regulation of TLR3 expression by type I IFN amplifies the response to TLR3 ligands.

TLR3 is expressed in conventional DC (cDCs) subpopulations and macrophages as well as non-immune cells, such as fibroblasts and epithelial cells, and the cellular localization of TLR3 varies between different cell types. In conventional DCs TLR3 is thought to be localized in intracellular vesicular structures ([@bib74]). High expression of TLR3 is seen in the subset of CD8*α* ^+^CD4^−^ DC which phagocytose apoptotic cells, including dying cells that are infected by RNA viruses ([@bib27]).

In other cell types such as fibroblasts or epithelial cells TLR3 is expressed on the cell surface ([@bib74]). Epithelial expression of TLR3 can be found in many different organs including the airways as well as the gastrointestinal and urogenital system. Furthermore, strong expression of TLR3 is detectable in the brain suggesting a specific role in response to viral infections of the central nervous system. Despite this wide expression pattern TLR3 does not appear to be essential for the initial antiviral immune response in several mouse models of viral infection ([@bib26]; [@bib69]).

Downstream signaling of TLR3 is unique among all TLRs, because it is entirely MyD88-independent and is mediated by the cytosolic TIR-domain containing adaptor protein TRIF. TRIF is recruited to the cytoplasmatic TIR domain of TLR3 and interacts with a set of different signaling molecules and kinases which in turn initiate activation of NF*κ*B or IRF3 and IRF7 leading to type I interferon induction. Interaction of TRIF with TRAF3 allows complex formation with the non-canonical IKKs-TBK1 and IKK*ε* leading to the activation of IRF3 and IRF7, which form homo- or heterodimers upon phosphorylation and are then translocated to the nucleus to induce type I IFN and IFN inducible gene expression ([@bib28]; [@bib98]; [@bib112]). NF*κ*B activation by TLR3 ligands is mediated in two ways -- via association of TRIF with RIP1 or via interaction of TRIF with TRAF6, which in turn activates TAK1. Both RIP1 and TAK1 mediate activation of canonical IKKs (IKK*α*, IKK*β*) resulting in I*κ*B degradation and NF*κ*B translocation to the nucleus ([@bib76]; [@bib93]).

The role of TLR3 in antiviral immunity remains unclear so far. Most studies did not find an essential role of TLR3 for the generation of effective antiviral immune responses. TLR3-deficient mice are as susceptible to reovirus, VSV and LCMV infection as wild-type mice and there was no significant difference in generating specific CD4 and CD8 T cell responses to these viruses ([@bib26]). Interestingly, however, virally induced CNS injury was improved by TLR3-deficiency suggesting that inflammatory responses mediated by TLR3 are at least partially responsible for a breakdown of the blood--brain barrier which facilitates and enhances virus entry into the brain. TLR3-deficient mice survived viral CNS infection with West Nile virus ([@bib110]), which is characterized by meningitis and encephalitis induced by inflammatory mediators, for longer time periods than wild-type mice. Similarly, in murine influenza A virus infection TLR3-mediated inflammatory responses in the lung contribute significantly to host morbidity and lethality. Despite higher pulmonary viral loads TLR3^−/−^ mice showed less inflammation and better survival ([@bib64]). Interestingly, human lung epithelial cells express proinflammatory cytokines including IL-6 and IL-8 upon infection with influenza A virus in a TLR3-dependent manner ([@bib65]), suggesting that TLR3-mediated inflammatory responses may also contribute to influenza virus-induced lung pathology in humans.

The role of TLR3 in MCMV infection is more controversial. Whereas [@bib26] claimed no impairment in antiviral response to MCMV in TLR3^−/−^ mice, another publication suggested a higher susceptibility to MCMV in the absence TLR3 ([@bib104]). In this study TLR3 deficiency results in higher splenic viral titers compared to wild-type mice. Similar observations were made when infecting TRIF^Lps2/Lps2^ mice with MCMV ([@bib39]). The increased viral load was accompanied by a decreased cytokine response which mostly affected type I IFN and to a lesser extent IL12p40 and IFN-*γ* produced by NK and NKT cells ([@bib104]).

Crosspriming occurs most efficiently in the specialized subpopulation of CD8*α* ^+^ DCs, which have a high capacity for internalization of apoptotic cells. TLR3 which is expressed at high levels in CD8*α* ^+^ DCs ([@bib27]) plays a critical role for crosspriming of CTLs directed against viruses that do not infect DCs directly. CD8*α* ^+^ DCs are activated by viral RNA contained in internalized virally infected apoptotic cells and crosspresent viral antigens to specific CD8^+^ T cells in a TLR3-dependent manner ([@bib96]).

Toll-like receptor 9
--------------------

TLR9 has been described to recognize bacterial DNA or synthetic oligodesoxyribonucleotides (ODN) containing specific unmethylated CpG sequence motifs. These can also be found in the genome of DNA viruses. Viruses recognized by TLR9 are HSV type 1 and 2 ([@bib38]; [@bib62]), MCMV ([@bib61]; [@bib70]; [@bib104]), adenovirus ([@bib9]) and baculovirus ([@bib1]). Recognition of HSV or MCMV by TLR9 of pDCs results in robust induction of type I interferon and inflammatory cytokines ([@bib61], [@bib62]; [@bib70]). CpG ODN class A, B and C have been designed to trigger primarily type I IFN response (A) or costimulatory molecule expression and inflammatory cytokine production (B) or both (C) in pDCs. CpG-B and CpG-C additionally trigger B cell stimulation via TLR9 ([@bib60]; [@bib109]; [@bib35]).

Induction of type I IFNs by TLR9 ligands in pDCs depends on retention of the ligand--receptor complex within early endosomes at a pH value between 6.2 and 5.5 ([@bib33]). Delivery of TLR9 ligands to late endosome with lower pH values (\<4.5) impairs the induction of type I IFNs and promotes inflammatory cytokine and costimulatory molecule expression in pDCs ([@bib33]). Early endosomal retention is achieved by using CpG-A, which forms aggregates or by transfecting CpG-B with cationic liposomes or delivering CpG DNA in the form of immune complexes ([@bib58]; [@bib75]; [@bib33]). TLR9 ligands delivered within herpes virus particles also seem to be retained long enough in the early endosomal compartment to trigger type I IFN responses efficiently.

Upon ligand binding the TIR domain of TLR9 recruits MyD88 which forms a supramolecular complex with TRAF6, IRAK1, IRAK4 and IRF7 ([@bib41]; [@bib55]). IRF7 becomes activated upon phosphorylation which results in homodimerization of IRF7 or heterodimerization of IRF3 and IRF7. These dimers then translocate to the nucleus and induce expression of type I interferon and interferon inducible genes. Several proteins were implicated in the phosphorylation of IRF7 including IRAK-1, IKK*α*, and a precursor of osteopontin ([@bib46]; [@bib99]; [@bib108]). Lack of IRAK1 abolishes IFN-*α* production and IRF7 activation in response to TLR7, TLR8 and TLR9 ligands ([@bib108]).

IRF7 plays the role of a "master regulator" in the induction of type I interferon and IFN inducible genes in response to viruses ([@bib42]). The currently accepted two step model of positive feedback regulation of type I interferon gene expression consists of an initial phase with activation of IRF7 expressed constitutively at low levels, formation of IRF7-homodimers or IRF7/IRF3-heterodimers and induction of small amounts of IFN-*β*/IFN-*α* and chemokines. During the second phase secreted type I IFNs signal via type I IFN receptor in an autocrine and paracrine manner. Downstream signaling of the type I IFN receptor induces a strong up-regulation of IRF7 production leading to full expression of type I IFN genes (positive feedback loop). Although pDCs constitutively express IRF7 at higher levels than other cells, they also depend on further up-regulation of IRF7 by type I IFN signaling to be able to sustain high level production of type I IFNs ([@bib40]; [@bib43]).

In contrast to pDCs, type I IFN production in myeloid DCs in response to DNA viruses is mediated by both TLR9-dependent and TLR9/MyD88-independent pathways. Downstream signaling of TLR9 in murine myeloid DCs shows differences compared to pDCs. In myeloid DCs IRF1 plays a crucial role in the downstream signaling of TLR9. IRF1^−/−^ mice show an impaired induction of IFN-*β*, iNOS and IL-12p35 upon stimulation with TLR9 ligand CpG-B, whereas type I interferon response of pDCs is not affected by lack of IRF1 ([@bib81]; [@bib95]).

What is the role of TLR9 for antiviral immunity *in vivo*? Several studies have described increased susceptibility of TLR9^−/−^ mice to systemic murine cytomegalovirus (MCMV) infection ([@bib104]; [@bib61]; [@bib23]). We could show that TLR9-dependent recognition of MCMV by pDCs and conventional DC is clearly involved in the innate immune response to MCMV. In the very early phase of systemic MCMV infection pDCs and conventional DCs release the first wave of type I interferons and inflammatory cytokines including IL-12. The expression of these cytokines peaks between 36 and 38 h post-infection ([@bib21]; [@bib83]) and triggers non-specific NK cell activation at this time point. Control of viral replication and clearance of the virus from infected organs during the first week of MCMV infection relies mostly on NK cells, which produce IFN-*γ* (mediated by IL-12 and IL-18) and kill infected cells ([@bib82]). We found a significant reduction in IFN-*α* and IL-12 serum levels in TLR9- and MyD88-deficient mice at 36 h after infection. However, IFN-*α* serum levels comparable to those of wild-type mice could be observed in TLR9- and MyD88-deficient mice at later time points suggesting the existence of an additional TLR9/MyD88-independent type I IFN induction mechanism with delayed kinetics. Loss of the early IFN-*α* peak is due to an impaired function of pDCs in TLR9^−/−^ mice as MCMV recognition and type I IFN production are TLR9-dependent in this cell type. pDC depletion *in vivo* led to markedly reduced IFN-*α* levels at 36 h after infection reflecting their almost exclusive role for IFN-*α* production at this early time point. In contrast to IFN-*α*, IL-12 production was severely impaired in TLR9- and MyD88-deficient mice at all time points reflecting the requirement of TLR9 for IL-12 responses to MCMV in all DC subpopulations. IFN-*γ* production by NK cells which is induced by IL-12 and IL-18 was also significantly reduced in the absence of TLR9 or MyD88. These defects in the innate immune response to MCMV correlated with higher viral titers in spleen and liver of TLR9^−/−^ and MyD88^−/−^ mice on the C57BL/6 background reflecting increased susceptibility to MCMV in the early phase of the infection ([@bib23]; [@bib61]).

A recent report showed that pDCs which are recruited to the vaginal mucosa after local infection with HSV-2 are activated to produce type I IFN in a TLR9-dependent manner, thus reducing local viral replication and pathology ([@bib72]). In two mouse models of local infection with HSV-1 (footpad or eye infection), however, we did not find a significant difference in viral titers between TLR9^−/−^ and MyD88^−/−^ mice and wild-type mice ([@bib62]). The requirement for TLR9 in the innate immune response to herpes viruses *in vivo* is influenced by the site of virus entry and the recruitment of DC subpopulations to the infected tissue. All of the described *in vivo* studies show that in addition to TLR9 other pattern recognition receptors and signaling pathways responding to herpes virus infection must exist, which can partially compensate for the lack of TLR9 and other MyD88-dependent receptors ([@bib62]; [@bib38]; [@bib72]). The cytosolic DNA receptor which has been described recently ([@bib101]; [@bib48]; [@bib106]) may also be involved in the TLR9-independent component of the immune response to herpes virus infections.

Toll-like receptor 7 and 8
--------------------------

TLR7 and TLR8 are both located on the X chromosome and are homologous to each other. GU-rich ssRNA sequences of viral or host origin, poly-U RNA and specific siRNA sequences are ligands for both receptors, whereas synthetic imidazoquinoline derivatives have been designed to specifically activate TLR7 or TLR8 or both receptors ([@bib36]; [@bib37]; [@bib25]; [@bib51]; [@bib44]; [@bib32]). TLR7 is expressed in human and murine pDCs, conventional DCs and B cells, whereas TLR8 seems to be functional mainly in human monocytes and myeloid DCs. The role of TLR8 in the murine immune system remains to be elucidated. Similar to what has been described for TLR9, activation of TLR7 and TLR8 by specific ligands occurs in the acidified endosomal compartment. The MyD88-dependent signal transduction pathway downstream of TLR7 and 8 is very similar to TLR9-mediated signaling.

Several viruses are recognized by pDCs in a TLR7-dependent manner including influenza virus ([@bib25]; [@bib7]), Newcastle disease virus (NDV) ([@bib53]), vesicular stomatitis virus (VSV) ([@bib71]), coronaviruses ([@bib18]) and RNA viruses ([@bib36]; [@bib10]). TLR7 does not seem to play an essential role in the innate immune response to RNA virus infection *in vivo*. We could not find a significant difference between MyD88^−/−^ and wild-type mice in the susceptibility to intranasal influenza virus infection and type I IFN response to intravenously injected influenza virus was only partially reduced in the MyD88-deficient animals ([@bib7]). At high viral doses type I IFN response to systemic VSV infection is TLR7-dependent and mediated by pDCs, whereas at lower doses TLR7-independent type I IFN induction pathways play the major role. A recent study demonstrates an essential function of TLR7 for the innate immune response to systemic coronavirus infection in mice ([@bib18]). pDCs, but not conventional DCs are capable of producing significant amounts of type I IFN in response to the rapidly replicating coronaviruses and this response is entirely TLR7-dependent. pDC depletion led to abrogation of type I IFN response and increased disease severity ([@bib18]). It can be concluded that TLR7 (and possibly TLR8 in the human system) contribute to the initiation of the antiviral immune response against viruses which specifically target pDCs. In addition the ubiquitously expressed RNA helicases provide protection against RNA viruses in all cell types (see below). Depending on the route and kinetics of infection, cellular tropism, viral entry and replication as well as immune evasion mechanisms of individual virus strains one or the other viral RNA recognition pathway may dominate the innate antiviral immune response *in vivo*.

What is the role of TLRs for antiviral immune responses in humans?
------------------------------------------------------------------

As suggested by the murine *in vivo* studies there is considerable redundancy in TLR-dependent and TLR-independent viral pattern recognition mechanisms also in the human system. IRAK-4-deficient patients are prone to invasive infection with pneumococci, but are resistant to natural viral infection ([@bib85]). IRAK4-deficient PBMC do not respond to any of the MyD88-dependent TLR ligands, but are capable of type I IFN production in response to many DNA and RNA viruses. There also seems to be considerable redundancy between different TLRs, because in contrast to the IRAK4-deficient patients, which show no significant defects in antiviral responses ([@bib85]), individuals with autosomal recessive deficiency in the intracellular protein Unc-93b have an impaired antiviral type I IFN response and are susceptible to HSV-1 encephalitis ([@bib16]). Unc-93b-deficiency prevents signaling in response to ligands of the endosomally localized TLR3, TLR7, TLR8 and TLR9 ([@bib105]). In addition, the Unc-93b protein, which is localized in the endoplasmic reticulum, is required for efficient crosspresentation and MHC class II presentation of exogenous antigens ([@bib105]). Therefore, Unc-93b-deficiency may affect innate and adaptive antiviral immune responses at the same time. No human deficiencies or mutation in the RIG-I/MDA5 pathway of RNA virus recognition have been described so far. However, the critical role of this major pathway for innate antiviral immune responses in humans is greatly supported by the existence of viral immune evasion strategies, which, for example, are employed by hepatitis C virus and paramyxoviruses and are directed against several signaling molecules in this pathway (see below).

RNA helicases sense intracellular viral RNA
===========================================

In addition to the TLRs, a new family of viral pattern recognition receptors consisting of RNA helicases retinoic acid inducible gene I (RIG-I), melanoma differentiation antigen 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) -- was discovered and characterized in the last 3 years. These molecules, which are localized in the cytosol, bind specific RNA molecules derived from the genome of different RNA viruses and, with the exception of LGP2 which does not signal itself, trigger a signaling cascade leading to the production of type I IFNs and of proinflammatory cytokines in response to viral infection.

RIG-I
-----

Retinoic-acid-inducible protein I (RIG-I) is a DExD/H box-containing RNA helicase that was originally identified as an enhancer of type I IFN expression in response to dsRNA poly (I:C) ([@bib113]). DExD/H box RNA helicases are defined by their ability to unwind dsRNA using their intrinsic ATPase activity. In addition to the C-terminal helicase domain RIG-I contains two caspase recruitment domains (CARD) at its N terminus ([@bib115]). CARDs are found in a number of caspases, but also in other proteins such as NOD1 and NOD2, involved in sensing intracellular bacterial products ([@bib47]). The functions of RIG-I have been analyzed in detail in the first publication by [@bib113] using deletion constructs of full length RIG-I. Overexpression of the N-terminal region of RIG-I (delta RIG-I) comprising the two tandem CARDs is sufficient to induce IRF3 and NF*κ*B activation even in the absence of a dsRNA stimulus or viral challenge. The mutant of RIG-I lacking the CARD domain is not capable of transmitting signals. This N-terminally truncated molecule even has a dominant negative effect since expression of this domain alone prevents activation of IRF3 by dsRNA transfection or NDV infection ([@bib113]).

Since CARDs are known to engage in homophilic protein--protein interactions in other signal transduction pathways, it was therefore likely that the CARDs of RIG-I interact with other CARD containing molecules to activate downstream signaling molecules. The adaptor protein that links RIG-I to the activation of TBK1/IKK*ε* and IKK*β* was identified and functionally characterized by four independent groups and designated as IFN-*β* promoter stimulator 1 (IPS-1) ([@bib56]), mitochondrial antiviral signaling protein (MAVS) ([@bib97]), virus-induced signaling adapter (VISA) ([@bib111]) and CARD adapter inducing IFN-*β* (CARDIF) ([@bib77]), respectively. IPS-1 contains an N-terminal CARD domain that interacts with the tandem CARD domains of RIG-I and a C-terminal hydrophobic transmembrane (TM) domain that localizes it to the outer mitochondrial membrane ([@bib97]). Deletion analyses have shown that both the CARD and the transmembrane domain are essential for the function of IPS-1. The mitochondrial localization of IPS-1 is essential for its activity because deletion of the TM domain, which leads to cytosolic expression of the protein, abolishes the signaling function of IPS-1. The binding of dsRNA to the helicase domain of RIG-I likely induces a conformational change that exposes the N-terminal CARD domains to recruit its signaling adaptor IPS-1. This interaction subsequently induces IFN-*α*/INF-*β* and IFN-induced antiviral effector mechanisms that suppress virus replication ([@bib78]).

In a recent publication Saito et al. reported that an internal repressor (or regulatory) domain (RD) at the C-terminus controls RIG-I multimerization and IPS-1 interaction during virus infection and RNA binding ([@bib91]). Expression of the C-terminal RD domain, encompassing the amino acids 735--925 of the RIG-I protein, prevents signaling to the IFN-*β* promoter and increased cellular permissiveness to hepatitis C virus, whereas deletion of the RIG-I RD results in constitutive signaling. Saito et al. suggest a model of RIG-I autoregulation and signaling predicting that in resting cells the C-terminal RD mediates a conformation of RIG-I that masks the CARDs from signaling. Once the cell is infected with virus, RIG-I activation and signaling occurs in a stepwise manner involving dsRNA binding and conformational changes that subsequently facilitate self-association and interaction with the IPS-1 signaling adaptor. These conformational changes comprising displacement of the RD and unmasking of the CARDs for signaling via IPS-1 might be triggered by ATP hydrolysis. Saito et al. also identified an analogous RD within the C terminus of LGP2 suggesting that LGP2 might inhibit RIG-I through their RD interactions. LGP2 is a close relative of RIG-I, which lacks the CARDs, but is capable of binding dsRNA ([@bib114]). Thus, LGP2 may act as a postinduction repressor of RIG-I signaling ([@bib88]).

From several studies it is known that RIG-I is essential for antiviral responses to a specific set of RNA viruses belonging to *Flaviviridae*, *Paramyxoviridae*, *Orthomyxoviridae* and *Rhabdoviridae* ([@bib54]; [@bib102]; [@bib113]). Since RNA is a fundamental entity of most living organisms and is found in abundance in host cells, a molecular pattern must exist that enables RIG-I to discriminate between viral RNA and host RNA species in the cytoplasm of infected cells to prevent constant induction of type I IFNs which would lead to autoimmune responses. Two recent studies have identified features of viral RNA that are structurally different to host RNA. [@bib45] demonstrated that ssRNA synthesized *in vitro* acquires a 5′-triphosphate moiety which is crucial for IFN production in host cells. Furthermore, they demonstrated that RNA isolated from Rabies virus (RV) infected cells is a potent IFN inducer, whereas RNA from non-infected cells and dephosphorylated RNA isolates abrogated this IFN response. The 5′-phosphorylation status and the absence of a 7-methyl-guanosine cap provided by the viral polymerase is critical for recognition by RIG-I. Taken together, the results of [@bib45] show that RIG-I directly recognizes 5′-triphosphate single stranded or double stranded RNA independently of viral replication. In the second study, [@bib86] found that Influenza A virus, which is known to be sensed by both RIG-I and TLR3, did not generate dsRNA upon infection of bone-marrow-derived dendritic cells. Moreover, they observed that Influenza virus ssRNA, which is uncapped and bears 5′-triphosphates, associated with and activated RIG-I.

IPS-1 functions as critical link between viral detection by RIG-I and the downstream signaling events leading to interferon production. This receptor--adapter interaction results in the activation of the noncanonical kinases TBK1/IKK*ε*, which in turn induces dimerization of phosphorylated IRF3 and IRF7 and translocation to the nucleus where they activate the transcription of type I IFN genes ([@bib56]). Coimmunoprecipitation experiments suggest that IPS-1 interacts with TBK1 and recruits endogenous IRF3 in a virus-inducible manner ([@bib111]). Recently, TRAF3 was shown to be critically involved in IPS-1-mediated IFN-*α* production and antiviral responses through a direct interaction between the TRAF domain of TRAF3 and a TRAF interaction motif within IPS-1 ([@bib90]). There is evidence that the TBK1/IKK*ε* adaptor protein TANK plays a role in IPS-1-TRAF3-mediated activation of TBK1/IKK*ε* ([@bib34]). RIP1 and FADD are additional molecules that have been reported to be required for type I IFN production in response to dsRNA ([@bib6]).

Another branch of IPS-1 signaling leads to the activation of the IKK complex resulting in activation of NF*κ*B that controls the expression of genes encoding inflammatory responses, but also expression of IFN-*β*. Previous work showed that IPS-1 activates a NF*κ*B-dependent reporter construct in cultured cells ([@bib73]). One of the key signaling proteins in the NF*κ*B pathway is TRAF6, an essential upstream regulator of the IKK complex. IPS-1 binds to TRAF6 upon overexpression in mammalian cells and in a yeast-two hybrid screen ([@bib97]; [@bib111]). [@bib111] reported that endogenous IPS-1 also interacts with TRAF6. In addition, they showed that IPS-1 fails to activate NF*κ*B in the absence of TRAF6. [@bib97] reported that virus-mediated induction of the IFN-*β* gene is not abolished in TRAF6 deficient cells and that a mutant IPS-1 protein lacking the TRAF6 binding domain is still capable of inducing IFN-*β*. Thus, TRAF6 seems to be required for NF*κ*B activation but not IFN-*β* induction downstream of IPS-1 which is mainly mediated by TBK1/IKK*ε*.

*In vitro* studies performed with primary cells obtained from RIG-I knockout mice confirmed that RIG-I plays an essential role in eliciting immune responses against specific negative strand and positive strand RNA viruses such as NDV, SeV, VSV, Japanese encephalitis virus (JEV) and Influenza virus in various cell types with the exception of pDCs ([@bib54]). The experiments demonstrated that type I IFN production by RIG-I deficient fibroblasts and conventional DCs is severely impaired in response to these RNA viruses. In contrast, pDCs lacking RIG-I show normal type I IFN responses to NDV or VSV for example, as the pDC response to these viruses is mediated by TLR7 ([@bib53]). The studies performed so far indicate that the RNA helicases RIG-I and MDA5 as well as their common signaling adaptor IPS-1 are dispensible for viral triggering of type I IFN responses in pDCs ([@bib54]).

MDA5
----

MDA5 is another DExD/H-box-containing RNA helicase that is involved in the sensing of intracellular dsRNA and the induction of type I IFN in response to RNA viruses ([@bib5]). It is the closest relative of RIG-I, exhibiting 23 and 35% amino acid homology in the N-terminal CARD and C-terminal helicase domain, respectively. It was reported in a previous publication, that MDA5, which was then called Helicard, is cleaved by caspases upon induction of apoptosis, thereby separating the CARD domains from the C-terminal helicase domain, which localizes to the nucleus where it is involved in DNA degradation and nuclear remodelling during apoptotic cell death ([@bib59]). Furthermore, MDA5 has been implicated in the regulation of the growth and differentiation of melanoma cells ([@bib52]). MDA5 is ubiquitously expressed in low abundance and similarly to RIG-I and LGP2 its expression is induced by type I IFN. Like RIG-I, MDA5 interacts with the adapter protein IPS-1 upon ligand binding leading to activation of protein kinases that subsequently activate transcription factors IRF3, IRF7 and NF*κ*B, respectively. It was found recently by [@bib93] that in contrast to RIG-I, the C-terminal regulatory domain of MDA5 did not exert a repressor function on MDA5 signaling, which was also not inhibited by LGP2. MDA5 overexpression in cell lines even at low levels induces IFN-*β* promoter activity in the absence of ligand binding. Thus, MDA5 expression which is up-regulated in response to type I IFN signaling may function as an amplifier of type I IFN production even in the absence of specific MDA5 ligands.

Although RIG-I and MDA5 are similar proteins inducing synthesis of type I IFN via the same signaling pathway, they are specialized in the recognition of different viruses. *In vitro* studies performed with embryonic fibroblasts and conventional DCs derived from MDA5 knockout mice have shown that MDA5 is specifically required for the recognition of intracellular poly (I:C) dsRNA (but not *in vitro* transcribed PPP-RNA) and picornaviruses such as encephalomyocarditis virus (EMCV), Theiler\'s virus and Mengo virus, whereas RIG-I was not necessary for the response to poly (I:C) or picornaviruses ([@bib54]; [@bib31]). In addition, it was shown that MDA5 might also play a role in the measles virus (MV) induced activation of IFN-*β* mRNA synthesis since A549 cells transfected with MDA5 showed a strong activation of the IFN-*β* promoter upon infection with MV. In contrast, the virus did not enhance reporter gene activity in cells that overexpressed RIG-I ([@bib12]). MDA5 was not required for recognition of VSV, NDV, JEV, SeV and influenza virus, indicating that RIG-I was the predominant pattern recognition receptor for these viruses. It is currently unknown which specific viral RNA motifs in picornaviruses are recognized by MDA5 and how ligand specificity is determined on the molecular level.

RIG-I and MDA5 are essential mediators of antiviral immunity *in vivo*
----------------------------------------------------------------------

The *in vivo* relevance of the RIG-I and MDA5 pathways for innate antiviral immune responses was addressed by the generation of knockout mice. The specific susceptibility of MDA5-deficient mice to encephalomyocarditis virus (EMCV) infection was shown in two studies ([@bib54]; [@bib31]). In a direct comparison with IFNAR^−/−^ and MyD88^−/−^ mice [@bib54] could show that survival upon EMCV infection is as dramatically reduced in MDA5^−/−^ mice as in IFNAR^−/−^ mice. MyD88-deficient mice were only slightly more susceptible to EMCV infection than wild-type mice. Survival after EMCV infection was not affected by RIG-I- or TLR3-deficiency. Studies in the IPS-1 knockout mouse confirmed the dramatic reduction in the innate immune response to EMCV infection, which correlated with increased viral titers and decreased survival, in the absence of the central downstream signaling adaptor of MDA5 and RIG-I ([@bib63]). Only few *in vivo* experiments with RIG-I-deficient mice have been published so far, because for unknown reasons most of the RIG-I-knockout mice (on a 129/C57BL/6 mixed background) died *in utero* or within a few weeks after birth ([@bib54]). After crossing with ICR mice healthy RIG-I^−/−^ mice were obtained and compared with littermate controls in the JEV and VSV infection models. RIG-I^−/−^ mice were more susceptible to JEV and VSV infection than wild-type mice and this correlated with reduced type I IFN responses. MyD88-dependent type I IFN production induced by JEV and VSV played only a minor role in these infection models ([@bib54]). In accordance with these results IPS-1-deficient mice succumbed rapidly to VSV infection ([@bib103]). As pointed out by the study of [@bib103], type I IFN responses to systemic VSV infection were not entirely abrogated in IPS-1-deficient mice, suggesting that TLR7-dependent pDC-mediated type I IFN release at least partially compensates for the dysfunctional RNA helicase pathway, but this compensatory mechanism cannot prevent death after infection with high doses of VSV.

The RNA helicase pathway as target for viral immune evasion strategies
----------------------------------------------------------------------

Viruses have adapted strategies to evade or inhibit key elements of antiviral immunity. A number of viral proteins inhibit host innate immune responses, prevent viral antigen presentation and abrogate induction of cell death. Since the cytoplasmic RIG-I/MDA5 system is critical for host defense against RNA viruses, the signaling cascades induced by these sensors are also targeted by viruses. Various proteins encoded by RNA viruses have been shown to antagonize the cytoplasmic RNA helicase pathways.

IFN antagonists of negative strand RNA viruses can interfere with this pathway by hiding their RNA (Influenza A virus NS1 protein) or binding to the dsRNA receptor (Paramyxovirus V proteins) or preventing activation of downstream factors such as IRF3 (Ebola virus VP35, Rhabdovirus P), respectively.

The non-structural protein 1 (NS1) of the Influenza viruses is a dsRNA-binding protein that acts as an IFN antagonist ([@bib30]). By binding to dsRNA NS1 disguises the viral dsRNA pattern from the cytoplasmic receptors and inhibits IFN-*α*/INF-*β* induction via IRF3 ([@bib29]; [@bib107]). RIG-I was recently demonstrated to be essential for the induction of IFN-*β* by Influenza virus in murine cells. Furthermore, it was observed that NS1 colocalizes with RIG-I ([@bib79]), suggesting that NS1 forms a complex with RIG-I and IPS-1 during viral infection, resulting in inhibition of further downstream signaling. Respiratory syncytial virus (RSV) specifically interferes with IRF3 activation and IFN-*β* response: Two viral proteins of RSV, NS1 and NS2, are involved in blocking the pathway leading to IRF3 phosphorylation, although the activation of NF*κ*B and AP-1 is unaffected ([@bib14]). IRF3 phosphorylation by TBK1 was identified as target of the Rabies virus phosphoprotein P ([@bib15]). Recently it was shown that the NY-1 Hantavirus G1 cytoplasmic tail inhibits RIG-I- and TBK1-directed interferon responses ([@bib3]).

The V proteins of paramyxoviruses target MDA5, but not RIG-I. The V proteins of this diverse group of viruses bind MDA5 via their highly conserved cysteine-rich C-terminal domain. This suggests that paramyxoviruses use this interaction to reduce the amount of IFN released by infected cells ([@bib5]; [@bib19]). Furthermore, it was shown that MDA5 is also a target of picornaviruses since MDA5 is degraded in poliovirus-infected cells. Interestingly, MDA5 is not directly cleaved by virus-encoded proteinases. Degradation of MDA5 in poliovirus-infected cells occurs in a proteasome- and caspase-dependent manner and correlates with the induction of apoptosis in poliovirus-infected cells. Poliovirus-induced MDA5 cleavage attenuates the production of type I IFN, thereby allowing higher levels of viral replication and dissemination in the host ([@bib8]).

Hepatitis C virus (HCV) encodes the protease NS3/4A which targets IPS-1 by cleaving it at position Cys-508, thereby dislocating it from the mitochondrial membrane and thus abrogating further downstream signaling to type I IFN and NF*κ*B-dependent target gene expression ([@bib67]; [@bib77]). Interestingly, IPS-1 was also found to be localized to the cytosol and not the mitochondria in liver tissue from patients chronically infected with HCV ([@bib68]). Inhibitors of the HCV NS3/4A, which have originally been designed to inhibit HCV replication, are able to prevent IPS-1 cleavage and restore the RIG-I-mediated innate immune response to HCV ([@bib50]). Therefore, NS3/4A inhibitors which are already being tested in clinical trials may have therapeutic potential for chronic hepatitis C infection. The fact that RNA viruses have developed so many effective strategies to interfere with the RNA helicase pathway of viral recognition during coevolution with their host provides further proof for the central role of this pathway in antiviral immune defense.
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